Ralph J. Riello III
Research & Publications
Biography
News
Locations
Research Summary
Dr. Riello’s research interests include pharmacist-driven anticoagulation stewardship initiatives involving systems quality improvement for direct oral anticoagulants, reversal of factor Xa inhibitor associated life-threatening bleeding, and optimizing in-hospital management of acute decompensated heart failure by promoting adherence to guideline-directed medical therapy for heart failure patients with reduced and preserved ejection fraction, including the use of SGLT-2 inhibitors to reduce cardiovascular death and rehospitalization risk independent of diabetes status. He is an investigator on several industry and National Institute of Health sponsored clinical trials with a multitude of peer-reviewed articles, abstracts, and book chapters in these budding therapeutic arenas. Much of Dr. Riello's current research portfolio centers around the design and implementation of pragmatic, randomized controlled trials embedded within the electronic health record system to overcome clinical inertia and drive evidence-based medical care with clinical decision support technology for patients with cardiovascular, renal, and metabolic disease at a population health level in a cost-effective, yet scalable fashion. Please visit The PRagmatic trial Of Messaging to Provider Trials (PROMPT) research website to learn more about PROMPT-HF, PROMPT-Lipid, PROMPT-MRA and other ongoing studies.
Coauthors
Research Image
Selected Publications
- Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trialGhazi L, Yamamoto Y, Fuery M, O'Connor K, Sen S, Samsky M, Riello R, Dhar R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Electronic health record alerts for management of heart failure with reduced ejection fraction in hospitalized patients: the PROMPT-AHF trial. European Heart Journal 2023, 44: 4233-4242. PMID: 37650264, DOI: 10.1093/eurheartj/ehad512.
- Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized TrialGhazi L, Yamamoto Y, Riello RJ, Coronel-Moreno C, Martin M, O'Connor KD, Simonov M, Huang J, Olufade T, McDermott J, Dhar R, Inzucchi SE, Velazquez EJ, Wilson FP, Desai NR, Ahmad T. Electronic Alerts to Improve Heart Failure Therapy in Outpatient Practice A Cluster Randomized Trial. Journal Of The American College Of Cardiology 2022, 79: 2203-2213. PMID: 35385798, DOI: 10.1016/j.jacc.2022.03.338.
- ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo?Riello RJ, Pitt B. ARNI and MRA Combination in PARAGON-HF: Odd Couple or Dynamic Duo? JACC. Heart Failure 2021, 9: 25-27. PMID: 33309576, DOI: 10.1016/j.jchf.2020.10.005.
- Empagliflozin in Heart FailureGriffin M, Rao VS, Ivey-Miranda J, Fleming J, Mahoney D, Maulion C, Suda N, Siwakoti K, Ahmad T, Jacoby D, Riello R, Bellumkonda L, Cox Z, Collins S, Jeon S, Turner JM, Wilson FP, Butler J, Inzucchi SE, Testani JM. Empagliflozin in Heart Failure. Circulation 2020, 142: 1028-1039. PMID: 32410463, PMCID: PMC7521417, DOI: 10.1161/circulationaha.120.045691.
- Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case seriesGriffin M, Riello R, Rao VS, Ivey-Miranda J, Fleming J, Maulion C, McCallum W, Sarnak M, Collins S, Inzucchi SE, Testani JM. Sodium glucose cotransporter 2 inhibitors as diuretic adjuvants in acute decompensated heart failure: a case series. ESC Heart Failure 2020, 7: 1966-1971. PMID: 32476296, PMCID: PMC7373933, DOI: 10.1002/ehf2.12759.
- Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart FailureClarke JD, Riello R, Allen LA, Psotka MA, Teerlink JR, Lindenfeld J, Desai NR, Ahmad T. Effect of Inotropes on Patient-Reported Health Status in End-Stage Heart Failure. Circulation Heart Failure 2021, 14: e007759. PMID: 33530705, DOI: 10.1161/circheartfailure.120.007759.
- Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart FailureRao VS, Ivey-Miranda JB, Cox ZL, Riello R, Griffin M, Fleming J, Soucier R, Sangkachand P, O'Brien M, LoRusso F, D'Ambrosi J, Churchwell K, Mahoney D, Bellumkonda L, Asher JL, Maulion C, Turner JM, Wilson FP, Collins SP, Testani JM. Natriuretic Equation to Predict Loop Diuretic Response in Patients With Heart Failure. Journal Of The American College Of Cardiology 2021, 77: 695-708. PMID: 33573739, PMCID: PMC8114781, DOI: 10.1016/j.jacc.2020.12.022.
- Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist UseClark K, Victoria-Castro A, Ghazi L, Yamamoto Y, Coronel-Moreno C, Kadhim B, Riello R, O'Connor K, Ahmad T, Wilson F, Desai N. Rationale, Design, and Patient Characteristics of a Cluster-Randomized Pragmatic Trial to Improve Mineralocorticoid Antagonist Use. JACC Heart Failure 2023, 12: 322-332. PMID: 37943221, DOI: 10.1016/j.jchf.2023.08.025.
- Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison.Ostrominski JW, DeFilippis EM, Bansal K, Riello RJ 3rd, Bozkurt B, Heidenreich PA, Vaduganathan M. Contemporary American and European Guidelines for Heart Failure Management: JACC: Heart Failure Guideline Comparison. JACC Heart Fail 2024 PMID: 38583167, DOI: 10.1016/j.jchf.2024.02.020.
- Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter?Hu J, Schwann A, Tan J, Nuqali A, Riello R, Beasley M. Sequencing Quadruple Therapy for Heart Failure with Reduced Ejection Fraction: Does It Really Matter? Cardiology Clinics 2023, 41: 511-524. PMID: 37743074, DOI: 10.1016/j.ccl.2023.06.007.
- Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trialGhazi L, O'Connor K, Yamamoto Y, Fuery M, Sen S, Samsky M, Riello R, Huang J, Olufade T, McDermott J, Inzucchi S, Velazquez E, Wilson F, Desai N, Ahmad T. Pragmatic trial of messaging to providers about treatment of acute heart failure: The PROMPT-AHF trial. American Heart Journal 2022, 257: 111-119. PMID: 36493842, DOI: 10.1016/j.ahj.2022.12.002.
- Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID)Shah NN, Ghazi L, Yamamoto Y, Martin M, Simonov M, Riello RJ, Faridi KF, Ahmad T, Wilson FP, Desai NR. Rationale and design of a pragmatic trial aimed at improving treatment of hyperlipidemia in outpatients with very high risk atherosclerotic cardiovascular disease: A pragmatic trial of messaging to providers about treatment of hyperlipidemia (PROMPT-LIPID). American Heart Journal 2022, 253: 76-85. PMID: 35841944, PMCID: PMC9936562, DOI: 10.1016/j.ahj.2022.07.002.
- Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF)Ghazi L, Desai NR, Simonov M, Yamamoto Y, O'Connor KD, Riello RJ, Huang J, Olufade T, McDermott J, Inzucchi SE, Velazquez EJ, Wilson FP, Ahmad T. Rationale and design of a cluster-randomized pragmatic trial aimed at improving use of guideline directed medical therapy in outpatients with heart failure: PRagmatic trial of messaging to providers about treatment of heart failure (PROMPT-HF). American Heart Journal 2021, 244: 107-115. PMID: 34808104, DOI: 10.1016/j.ahj.2021.11.010.
- Adverse drug effects across patients with heart failure: a systematic review.Butzner M, Riello RJ, Sarocco P, Desai N. Adverse drug effects across patients with heart failure: a systematic review. The American Journal Of Managed Care 2022, 28: e113-e120. PMID: 35404555, DOI: 10.37765/ajmc.2022.88844.
- A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular DiseaseAhmad T, Riello RJ, Inzucchi SE. A Practical Guide for Cardiologists to the Pharmacological Treatment of Patients with Type 2 Diabetes and Cardiovascular Disease. European Cardiology Review 2021, 16: e11. PMID: 33897837, PMCID: PMC8054345, DOI: 10.15420/ecr.2020.01.r1.
- Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing.Harrigan JJ, Hubbard RA, Thomas S, Riello RJ, Bange E, Mamtani M, Mamtani R. Association Between US Administration Endorsement of Hydroxychloroquine for COVID-19 and Outpatient Prescribing. Journal Of General Internal Medicine 2020, 35: 2826-2828. PMID: 32542496, PMCID: PMC7295147, DOI: 10.1007/s11606-020-05938-4.
- Adoption of sacubitril-valsartan in the Medicare populationKahn PA, Riello RJ, Ahmad T, Desai NR. Adoption of sacubitril-valsartan in the Medicare population. American Heart Journal 2020, 223: 81-83. PMID: 32179259, DOI: 10.1016/j.ahj.2020.02.009.
- Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s ExperienceGriffin M, Soufer A, Goljo E, Colna M, Rao VS, Jeon S, Raghavendra P, D'Ambrosi J, Riello R, Coca SG, Mahoney D, Jacoby D, Ahmad T, Chen M, Tang WHW, Turner J, Mullens W, Wilson FP, Testani JM. Real World Use of Hypertonic Saline in Refractory Acute Decompensated Heart Failure A U.S. Center’s Experience. JACC Heart Failure 2020, 8: 199-208. PMID: 32035891, PMCID: PMC7814403, DOI: 10.1016/j.jchf.2019.10.012.
- Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trialsAhmad T, Miller PE, McCullough M, Desai NR, Riello R, Psotka M, Böhm M, Allen LA, Teerlink JR, Rosano GMC, Lindenfeld J. Why has positive inotropy failed in chronic heart failure? Lessons from prior inotrope trials. European Journal Of Heart Failure 2019, 21: 1064-1078. PMID: 31407860, PMCID: PMC6774302, DOI: 10.1002/ejhf.1557.
- A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart FailureSoufer A, Riello RJ, Desai NR, Testani JM, Ahmad T. A Blueprint for the Post Discharge Clinic Visit after an Admission for Heart Failure. Progress In Cardiovascular Diseases 2017, 60: 237-248. PMID: 28826671, DOI: 10.1016/j.pcad.2017.08.004.
- Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic MedicationsYoung G, Bansal K, Riello R, Clark K, Dhruva S, Faridi K, Desai N. Medicare Coverage and Patient Out-of-Pocket Costs for Cardiovascular-Kidney-Metabolic Medications. JAMA Network Open 2024, 7: e2412437. PMID: 38771578, PMCID: PMC11109768, DOI: 10.1001/jamanetworkopen.2024.12437.
- Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare BeneficiariesReinhardt SW, Clark KAA, Xin X, Parzynski CS, Riello R, Sarocco P, Ahmad T, Desai NR. Thirty-Day and 90-Day Episode of Care Spending Following Heart Failure Hospitalization Among Medicare Beneficiaries. Circulation Cardiovascular Quality And Outcomes 2022, 15: e008069. PMID: 35861780, DOI: 10.1161/circoutcomes.121.008069.
- Heart Failure with Reduced Ejection FractionRiello RJ. In: PSAP 2022 Book – Cardiology [Internet] Gale SM, editor. Lenexa: American College of Clinical Pharmacy; 2022. [cited 2024 April 15]. Heart failure with reduced ejection fraction. Available from: https://www.accp.com/docs/bookstore/psap/p2022b1_sample.pdf.
- Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis.Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. Venous thromboembolism in acute medically ill patients: identifying unmet needs and weighing the value of prophylaxis. The American Journal Of Managed Care 2018, 24: s468-s474. PMID: 30452198.
- Best practices for implementing venous thromboembolism prophylaxis across the continuum of care.Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. Best practices for implementing venous thromboembolism prophylaxis across the continuum of care. The American Journal Of Managed Care 2018, 24: s483-s488. PMID: 30452200.
- The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients.Dobesh PP, Ahuja T, Davis GA, Fatodu H, Francis WH, Hull FP, Johnson GL, Lenchus JD, Lenoir JG, McPherson C, Nemeth J, Riello RJ. The use of betrixaban for extended prophylaxis of venous thromboembolism events in hospitalized, high-risk patients. The American Journal Of Managed Care 2018, 24: s475-s482. PMID: 30452199.
- Essential Elements of Early Post Discharge Care of Patients with Heart FailureSoucier RJ, Miller PE, Ingrassia JJ, Riello R, Desai NR, Ahmad T. Essential Elements of Early Post Discharge Care of Patients with Heart Failure. Current Heart Failure Reports 2018, 15: 181-190. PMID: 29700697, DOI: 10.1007/s11897-018-0393-9.